Pulmatrix

Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is initially focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with ABPA, and PUR1800, a narrow spectrum kinase inhibitor in lung cancer. Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by achieving optimal local drug concentrations and reducing systemic side effects to improve patient outcomes.

Pulmatrix headquartered in United States, North America, operates in the Biotechnology, Pharmaceutical, Therapeutics sector. The company focuses on Biotechnology and has secured $17.8B in funding across 120 round(s). With a team of 11-50 employees, Pulmatrix is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Pulmatrix, raised $30.2M. Discover more about their projects, partnerships, and impact on our platform.